Market Place
Sourcing Support
3D modelling of hip DXA reveals improvements in bone density of romosozumab
09 Sep 2022 //
UCB
Romosozumab substantially builds bone density in hip and spine
11 Nov 2020 //
EUREKALERT
Romosozumab for the treatment of osteoporosis
15 Jun 2020 //
SCIENCEDIRECT
UCB Shares Breadth of Innovative New Data from Rheumatology for EULAR 2020
04 Jun 2020 //
UCB
Amgen studying Otezla for coronavirus, Q1 results beat estimates
02 May 2020 //
PRESS RELEASE
UCB/Amgen’s Evenity finally cleared for osteoporosis in Europe
13 Dec 2019 //
PMLIVE
CHMP U-turn for Evenity
19 Oct 2019 //
PHARMATIMES
EVENITY® (Romosozumab) Receives Positive CHMP Opinion
17 Oct 2019 //
PR NEWSWIRE
EMA’s CHMP Rejects Another Drug Approved by US FDA
01 Jul 2019 //
RAPS
AZ bags two extensions in latest CHMP decisions
01 Jul 2019 //
PHARMATIMES
Amgen`s Evenity (Romosozumab-aqqg) Receives Supplemental Approval in US
11 Apr 2019 //
FDA
Once spurned, Amgen wins the FDA over with its osteoporosis drug Evenity
09 Apr 2019 //
ENDPTS
FDA Takes Steps to Make Naloxone an OTC Drug
18 Jan 2019 //
RAPS
Second time’s a charm for osteoporosis drug from Amgen, UCB
18 Jan 2019 //
ENDPTS
FDA staff largely unfazed by CV signal in Amgen osteoporosis drug trials
14 Jan 2019 //
ENDPTS
FDA staff largely unfazed by CV signal in Amgen osteoporosis drug trials
14 Jan 2019 //
ENDPTS
FDA Advisory Committee Calendar
08 Jan 2019 //
RAPS
UCB, Amgen refile osteoporosis drug Evenity
16 Jul 2018 //
PHARMA TIMES
Amgen, UCB Resubmit BLA For EVENITY™ (romosozumab) To FDA
13 Jul 2018 //
Amgen, UCB pitch back once-rejected osteoporosis drug to the FDA
13 Jul 2018 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.